Rossa Wk Chiu

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/12175524/publications.pdf

Version: 2024-02-01

67 papers	6,040 citations	109321 35 h-index	114465 63 g-index
67 all docs	67 docs citations	67 times ranked	7109 citing authors

#	Article	IF	Citations
1	Jagged Ends on Multinucleosomal Cell-Free DNA Serve as a Biomarker for Nuclease Activity and Systemic Lupus Erythematosus. Clinical Chemistry, 2022, 68, 917-926.	3.2	7
2	Effects of nucleases on cell-free extrachromosomal circular DNA. JCI Insight, 2022, 7, .	5.0	12
3	Single-Molecule Sequencing Enables Long Cell-Free DNA Detection and Direct Methylation Analysis for Cancer Patients. Clinical Chemistry, 2022, 68, 1151-1163.	3.2	22
4	Applications of genetic-epigenetic tissue mapping for plasma DNA in prenatal testing, transplantation and oncology. ELife, 2021, 10, .	6.0	19
5	Plasma DNA Profile Associated with DNASE1L3 Gene Mutations: Clinical Observations, Relationships to Nuclease Substrate Preference, and InÂVivo Correction. American Journal of Human Genetics, 2020, 107, 882-894.	6.2	37
6	Detection and characterization of jagged ends of double-stranded DNA in plasma. Genome Research, 2020, 30, 1144-1153.	5.5	61
7	Plasma DNA End-Motif Profiling as a Fragmentomic Marker in Cancer, Pregnancy, and Transplantation. Cancer Discovery, 2020, 10, 664-673.	9.4	152
8	The Biology of Cell-free DNA Fragmentation and the Roles of DNASE1, DNASE1L3, and DFFB. American Journal of Human Genetics, 2020, 106, 202-214.	6.2	127
9	Orientation-aware plasma cell-free DNA fragmentation analysis in open chromatin regions informs tissue of origin. Genome Research, 2019, 29, 418-427.	5.5	159
10	Enrichment of fetal and maternal long cellâ€free DNA fragments from maternal plasma following DNA repair. Prenatal Diagnosis, 2019, 39, 88-99.	2.3	8
11	Noninvasive reconstruction of placental methylome from maternal plasma DNA: Potential for prenatal testing and monitoring. Prenatal Diagnosis, 2018, 38, 196-203.	2.3	16
12	Circulating Nucleic Acids for Prenatal Diagnostics. , 2018, , 283-294.		0
13	Sequencing of Circulating Cell-free DNA during Pregnancy. New England Journal of Medicine, 2018, 379, 464-473.	27.0	221
14	Genomewide bisulfite sequencing reveals the origin and time-dependent fragmentation of urinary cfDNA. Clinical Biochemistry, 2017, 50, 496-501.	1.9	60
15	Analysis of Plasma Epsteinâ€“Barr Virus DNA to Screen for Nasopharyngeal Cancer. New England Journal of Medicine, 2017, 377, 513-522.	27.0	531
16	Non-invasive prenatal diagnosis of thalassemias using maternal plasma cell free DNA. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2017, 39, 63-73.	2.8	42
17	Cell-free DNA in maternal plasma and serum: A comparison of quantity, quality and tissue origin using genomic and epigenomic approaches. Clinical Biochemistry, 2016, 49, 1379-1386.	1.9	58
18	Noninvasive prenatal testing beyond genomic analysis. Current Opinion in Obstetrics and Gynecology, 2016, 28, 105-110.	2.0	10

#	Article	IF	Citations
19	Maternal Plasma Fetal DNA Fractions in Pregnancies with Low and High Risks for Fetal Chromosomal Aneuploidies. PLoS ONE, 2014, 9, e88484.	2.5	92
20	Noninvasive Prenatal Methylomic Analysis by Genomewide Bisulfite Sequencing of Maternal Plasma DNA. Clinical Chemistry, 2013, 59, 1583-1594.	3.2	131
21	Noninvasive Prenatal Determination of Twin Zygosity by Maternal Plasma DNA Analysis. Clinical Chemistry, 2013, 59, 427-435.	3.2	64
22	Cancer Genome Scanning in Plasma: Detection of Tumor-Associated Copy Number Aberrations, Single-Nucleotide Variants, and Tumoral Heterogeneity by Massively Parallel Sequencing. Clinical Chemistry, 2013, 59, 211-224.	3.2	447
23	High-Resolution Profiling of Fetal DNA Clearance from Maternal Plasma by Massively Parallel Sequencing. Clinical Chemistry, 2013, 59, 1228-1237.	3.2	202
24	Prenatal assessment of fetal chromosomal and genetic disorders through maternal plasma DNA analysis. Pathology, 2012, 44, 69-72.	0.6	14
25	Proteomic analysis reveals platelet factor 4 and beta-thromboglobulin as prognostic markers in severe acute respiratory syndrome. Electrophoresis, 2012, 33, 1894-1900.	2.4	23
26	Nucleic Acid Isolation. , 2012, , 1231-1237.		0
27	Plasma Nucleic Acids. , 2012, , 1397-1411.		0
28	Targeted Massively Parallel Sequencing of Maternal Plasma DNA Permits Efficient and Unbiased Detection of Fetal Alleles. Clinical Chemistry, 2011, 57, 92-101.	3.2	111
29	Non-invasive prenatal diagnosis by fetal nucleic acid analysis in maternal plasma: the coming of age. Seminars in Fetal and Neonatal Medicine, 2011, 16, 88-93.	2.3	67
30	Plasma nucleic acid analysis by massively parallel sequencing: pathological insights and diagnostic implications. Journal of Pathology, 2011, 225, 318-323.	4.5	22
31	Noninvasive Prenatal Diagnosis of a Case of Down Syndrome due to Robertsonian Translocation by Massively Parallel Sequencing of Maternal Plasma DNA. Clinical Chemistry, 2011, 57, 917-919.	3.2	25
32	Noninvasive Prenatal Detection of Trisomy 21 by an Epigeneticâ€“Genetic Chromosome-Dosage Approach. Clinical Chemistry, 2010, 56, 90-98.	3.2	115
33	Maternal Plasma DNA Analysis with Massively Parallel Sequencing by Ligation for Noninvasive Prenatal Diagnosis of Trisomy 21. Clinical Chemistry, 2010, 56, 459-463.	3.2	125
34	Synergy of Total PLAC4 RNA Concentration and Measurement of the RNA Single-Nucleotide Polymorphism Allelic Ratio for the Noninvasive Prenatal Detection of Trisomy 21. Clinical Chemistry, 2010, 56, 73-81.	3.2	57
35	Aberrant Concentrations of Liver-Derived Plasma Albumin mRNA in Liver Pathologies. Clinical Chemistry, 2010, 56, 82-89.	3.2	20
36	Epigenetic approaches for the detection of fetal DNA in maternal plasma. Chimerism, 2010, 1, 30-35.	0.7	26

#	Article	IF	Citations
37	Noninvasive Approaches to Prenatal Diagnosis of Hemoglobinopathies Using Fetal DNA in Maternal Plasma. Hematology/Oncology Clinics of North America, 2010, 24, 1179-1186.	2.2	18
38	Nicht-invasive prÃnatale Diagnostik fetaler chromosomaler Aneuploidien mittels NukleinsÃureanalyse des mÃ¼tterlichen Plasmas / Noninvasive prenatal diagnosis of fetal chromosomal aneuploidies by	0.6	0
39	Non-invasive prenatal diagnosis by single molecule counting technologies. Trends in Genetics, 2009, 25, 324-331.	6.7	95
40	Mass Spectrometric Detection of an SNP Panel as an Internal Positive Control for Fetal DNA Analysis in Maternal Plasma. Clinical Chemistry, 2007, 53, 141-142.	3.2	25
41	Mass Spectrometryâ€"Based Detection of Hemoglobin E Mutation by Allele-Specific Base Extension Reaction. Clinical Chemistry, 2007, 53, 2205-2209.	3.2	21
42	Detection of Restriction Enzymeâ€"Digested Target DNA by PCR Amplification Using a Stem-Loop Primer: Application to the Detection of Hypomethylated Fetal DNA in Maternal Plasma. Clinical Chemistry, 2007, 53, 1906-1914.	3.2	27
43	Epigenetic Analysis of RASSF1A Gene in Cell-Free DNA in Amniotic Fluid. Clinical Chemistry, 2007, 53, 796-798.	3.2	15
44	Non-invasive prenatal diagnosis of Down's syndrome. Lancet, The, 2007, 369, 1997.	13.7	11
45	Hypermethylation of RASSF1A in Human and Rhesus Placentas. American Journal of Pathology, 2007, 170, 941-950.	3.8	128
46	Hypermethylated RASSF1A in Maternal Plasma: A Universal Fetal DNA Marker that Improves the Reliability of Noninvasive Prenatal Diagnosis. Clinical Chemistry, 2006, 52, 2211-2218.	3.2	319
47	Plasma Î²-globin DNA as a prognostic marker in chest pain patients. Clinica Chimica Acta, 2006, 368, 110-113.	1.1	45
48	Automated extraction protocol for quantification of SARS-Coronavirus RNA in serum: an evaluation study. BMC Infectious Diseases, 2006, 6, 20.	2.9	5
49	Noninvasive Prenatal Detection of Fetal Trisomy 18 by Epigenetic Allelic Ratio Analysis in Maternal Plasma: Theoretical and Empirical Considerations. Clinical Chemistry, 2006, 52, 2194-2202.	3.2	156
50	Time Profile of Appearance and Disappearance of Circulating Placenta-Derived mRNA in Maternal Plasma. Clinical Chemistry, 2006, 52, 313-316.	3.2	46
51	Serum Amyloid A Is Not Useful in the Diagnosis of Severe Acute Respiratory Syndrome. Clinical Chemistry, 2006, 52, 1202-1204.	3.2	14
52	Serum Proteomic Fingerprints of Adult Patients with Severe Acute Respiratory Syndrome. Clinical Chemistry, 2006, 52, 421-429.	3.2	83
53	A simple and rapid approach for screening of SARS-coronavirus genotypes: an evaluation study. BMC Infectious Diseases, 2005, 5, 87.	2.9	4
54	Tracing SARS-Coronavirus Variant with Large Genomic Deletion. Emerging Infectious Diseases, 2005, 11, 168-170.	4.3	40

#	Article	IF	Citations
55	Detrimental Effect of Formaldehyde on Plasma RNA Detection. Clinical Chemistry, 2005, 51, 1074-1076.	3.2	5
56	Circulating Placental RNA in Maternal Plasma Is Associated with a Preponderance of 5â€² mRNA Fragments: Implications for Noninvasive Prenatal Diagnosis and Monitoring. Clinical Chemistry, 2005, 51, 1786-1795.	3.2	59
57	Lack of Dramatic Enrichment of Fetal DNA in Maternal Plasma by Formaldehyde Treatment. Clinical Chemistry, 2005, 51, 655-658.	3.2	52
58	Detection of Trisomy 21 by Quantitative Mass Spectrometric Analysis of Single-Nucleotide Polymorphisms. Clinical Chemistry, 2005, 51, 2358-2362.	3.2	37
59	The Biology and Diagnostic Applications of Fetal DNA and RNA in Maternal Plasma. Current Topics in Developmental Biology, 2004, 61, 81-111.	2.2	32
60	Circulating Nucleic Acids in Plasma/Serum III and Serum Proteomics Recent Developments in Fetal DNA in Maternal Plasma. Annals of the New York Academy of Sciences, 2004, 1022, 100-104.	3.8	14
61	The Biology and Diagnostic Applications of Plasma RNA. Annals of the New York Academy of Sciences, 2004, 1022, 135-139.	3.8	27
62	Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients. Journal of Clinical Virology, 2004, 31, 304-309.	3.1	516
63	Non-invasive prenatal diagnosis: on the horizon?. Pharmacogenomics, 2003, 4, 191-200.	1.3	13
64	Prenatal exclusion of Î² thalassaemia major by examination of maternal plasma. Lancet, The, 2002, 360, 998-1000.	13.7	267
65	Predominant Hematopoietic Origin of Cell-free DNA in Plasma and Serum after Sex-mismatched Bone Marrow Transplantation. Clinical Chemistry, 2002, 48, 421-427.	3.2	483
66	Noninvasive Prenatal Exclusion of Congenital Adrenal Hyperplasia by Maternal Plasma Analysis: A Feasibility Study. Clinical Chemistry, 2002, 48, 778-780.	3.2	145
67	Presence of Filterable and Nonfilterable mRNA in the Plasma of Cancer Patients and Healthy Individuals. Clinical Chemistry, 2002, 48, 1212-1217.	3.2	255